Advances in functional dyspepsia; traditional and beyond traditional
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20243997Keywords:
Colon care, Colon clear, Functional dyspepsia, H. pylori, ProbioticsAbstract
Background: Functional dyspepsia is a clinical syndrome defined by chronic or recurrent pain, heart burn or discomfort in the upper abdomen of a variable origin. A general agreement exists on the irrelevant role played by H. pylori in the pathophysiology of most cases of functional dyspepsia. Diagnosis is based on the clinical picture and detection of H. pylori. Specific sensitive diagnostic tests are available but H. pylori serum antibodies, though non-specific, is suggested because of being cost effective as the matter of H. pylori dyspepsia is a typical subject of cost-effectiveness. The efficacy of antibiotic treatment for non-ulcer dyspepsia is controversial, different trails have given conflicting results. Antibiotic eradication treatment for non-ulcer dyspepsia symptoms had no significant effect on quality of life compared with placebo and was found costlier if compared to antacid treatment.
Methods: A group of 32 males and females, children and adults with clinical symptoms of epigastric discomfort, hyperacidity and indigestion with or without distension were randomly included in study between October, 2023 and October, 2024. Their age ranged between 13-54 years; they were investigated for existence of H. pylori. Colon care and colon clear for natural eradications of H. pylori employed for them. They give natural probiotic supplements (acid butter milk) for 10 days in order to improve dyspeptic symptoms and they were followed up for 6-8 months.
Results: Marked clinical improvement and disappearance of most epigastric discomfort and dyspeptic symptoms.
Conclusions: H. pylori seems to be lately a major reason behind many cases of functional dyspepsia.
Metrics
References
Stanghellini V, De Ponti F, De Giorgio R, Barbara G, Tosetti C, Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs. 2003;63(9):869-92.
Farinha P, Gascoyne RD. Helicobacter pylori and MALT Lymphoma. Gastroenterology. 2005;128(6):1579-605.
Garcia-Altes A, Jovell AJ, Serra-Part M, Aymerich M. Management of Helicobacter pylori in duodenal ulcer: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2000;14(12):1631-8.
McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al. Symptomatic benefit from eradicating of Helicobacter pylori infection in patients with nonulcer dyspepsia. N Eng J Med. 1998;339:1869-74.
Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systemic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Goup. BMJ. 2000;321(7262):659-64.
Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995;79(4):475-9.
Nasrat AM, Nasrat SAM, Nasrat RM, Nasrat MM. Misconception and misbehavior towards Helicobacter pylori is leading to major spread of illness. General Med. 2015;S1:2.
Phull PS, Halliday D, Price AB, Jacyna MR. Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication. BMJ. 1996;312(7027):349-50.
Nasrat AM, Nasrat SAM, Nasrat RM, Nasrat MM. An alternate natural remedy for symptomatic relief of Helicobacter pylori dyspepsia. Gen Med. 2015;3(4):10.
Nasrat AM, Nasrat RM, Nasrat MM. Stop fighting the stomach bacterium Helicobacter pylori; esophageal reflux was not as such before the anti-H. pylori antibiotics. Am J Med Med Sci. 2017;7(4):196-201.
Sears CL. A dynamic partnership: Celebrating our gut flora. Anaerobe. 2005;11(5):247-51.
O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688-93.
Flint HJ, O’Toole PW, Walker AW. The human intestinal microbiota. Microbiology. 2010;156(11):3203-4.
Nasrat RM, Nasrat MM, Nasrat AM, Nasrat SAM. Improvement of idiopathic cardiomyopathy after colon clear. J Cardiol Res. 2015;6(2):249-54.
Ge Z. Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection. Expert Opin Ther Targets 2002;6(2):135-46.
Mendz GL, Hazell SL, Burns BP. Glucose utilization and lactate production by Helicobacter pylori. J Gen Microbiol. 1993;139(Pt 12):3023-8.
Mendz GL, Hazell SL. Fumarate catabolism in Helicobacter pylori. Biochem Mol Biol Int. 1993;31(2):325-32
Mendz GL, Hazell SL, van Gorkom L. Pyruvate metabolism in Helicobacter pylori. Arch Microbiol. 1994;162(3):187-92.
Hughes NJ, Clayton CL, Chalk PA, Kelly DJ. Helicobacter pylori porCDAB oorDABC genes encode distinct pyruvate: flavodoxin and 2-oxoglutarate: acceptor oxidoreductases which mediate electron transport to NADP. J Bacteriol 1998;180(5):1119-28.
Berg JM, Tymoczko JL, Stryer L. Biochemistry. WH Freeman and Company. 5th Ed: 2002;480.
Mendz GL, Ball GE, Meek DJ, Pyruvate metabolism in Campylobacter spp. Biochim Biophys Acta. 1997;1334(2-3):291-302.
Keskin D, Toroglu S. Studies on antimicrobial activities of solvent extracts of different species. J Environ Biol. 2011;32(2):251-6.
Guarizel L, Costa JC, Dutra LB, Mendes RF, Lima IVA, Scio E. Anti-inflammatory, laxative and intestinal motility effects of Senna macranthera leaves. Nat Prod Res. 2012;26(4):331-43.
Downloads
Published
How to Cite
Issue
Section
